Symptoms related cow’s milk proteins allergy (CMPA) usually improve between two to four weeks following an elimination diet, firstly with extensively hydrolyzed formulas (eHF). The aim of the EVA study was to observe the evolution of CMPA-related symptoms in real life after initiation of a whey-based extensively hydrolyzed formula (w-eHF, Althéra^®, Nestlé Health Science, Switzerland). This cross-sectional prospective non-interventional study was carried out alongside paediatricians in private practice in France between June 2019 and June 2020. Infants aged 0–3 years presenting with confirmed diagnosis or clinical symptoms suggesting CMPA were enrolled. Data were collected at enrolment (baseline visit) and three to five weeks later (follow-up visit). Symptoms were assessed using the Cow’s Milk-related Symptom Score (CoMiSS^®). The per protocol population included 135 infants. The average number of symptoms per infant significantly decreased under the study formula (from 2.81 to 1.36, p < 0.001) and the proportions of infants with any CMPA related symptoms decreased. Daily crying and regurgitation showed the largest decline, respectively −44.4% and −31.85% (p < 0.001). These results describe the early management of symptoms suspected to be related to CMPA in routine practice that was rarely described in the literature. The number and severity of symptoms decreased most of the cases after commencing the study formula.

In recent years, treatment of acute lymphoblastic leukemia (ALL) has improved substantially, leading to longer survival. This has necessitated a greater focus on health-related quality of life (HRQoL), but data are lacking. In a part-prospective, part-retrospective study, we enrolled 219 adults with ALL in France to assess the impact of key disease and treatment characteristics on HRQoL. Overall HRQoL and most specific QoL domain scores were consistently better among patients receiving front-line therapy, those currently in complete remission, and those who had previously received hematopoietic stem-cell transplantation. Furthermore, HRQoL was consistently impaired in patients with minimal residual disease present (MRD+). In multivariate analyses, multiple lines of therapy, MRD+, leukopenia, comorbidities, and anemia were significantly associated with impaired HRQoL. This study provides real-world data on HRQoL in adults with ALL in France and shows the positive impact of MRD-negative status on HRQoL.

Although e-cigarette use is increasing dramatically, numerous concerns persist regarding toxicity and their role in smoking cessation. We assessed beliefs and behavior regarding e-cigarettes in an adult French population. The 4th French nationwide observational survey, EDIFICE 4, was conducted among representative samples of 1602 laypersons (age, 40-75 years) from 12 June-10 July 2014, using the quota method. Profile, beliefs and behavior were assessed by phone interviews of the participating lay population with no history of cancer (N = 1463). Tobacco use, nicotine dependence (Fagerström test) and e-cigarette use were assessed. E-cigarette users represented 6% of the study lay population. E-cigarette users regarded e-cigarettes as helpful for quitting tobacco smoking and reducing the risk of lung cancer. Current dual users (e-cigarettes + cigarettes) were more likely to attempt to quit than current exclusively cigarette smokers (odds ratio, 3.15 [1.74-5.70]), and to consider themselves at higher risk for lung cancer (OR 3.85 [2.47-5.99]). They also considered e-cigarette vapor to be less toxic than tobacco smoke in terms of both active and passive exposure. Dual users typically consider themselves at higher risk for cancer and intend to quit smoking. Physicians should be made aware of this specific sub-population for whom e-cigarettes may be a useful trigger in the smoking cessation process.

The objective of this retrospective observational study was to estimate the prevalence of actinic keratosis (AK) in individuals aged ≥ 40 years in France, to describe the characteristics of affected patients, and to describe treatments. A representative panel of 20,000 households with ≥ 1 member aged ≥ 40 years were invited to participate. Participants who reported AK lesions diagnosed by a physician were eligible. The study questionnaire collected data on demographics, lesion characteristics, Fitzpatrick phototype, diagnosis, and treatments. In total, 15,246 questionnaires (78.5%) were returned and 639 responders were eligible. The adjusted prevalence of AK was 4.03% (95% CI: 3.73–4.35). Prevalence is probably underestimated due to data collection by self-report and low awareness of AK. 177 participants (27.7%) were aged < 65 years. AK was diagnosed by a dermatologist for 521 participants (81.6%). Some 200 participants (31.3%) had no lesions at the time of the survey and 243 (37.9%) had never been treated; 312 participants (78.6%) were prescribed physical treatment, principally cryotherapy; and 125 (31.5%) were prescribed topical treatment, principally 5-fluorouracil or imiquimod. In conclusion, improving diagnosis of AK in everyday clinical practice is important to ensure that all individuals with AK are treated optimally and encouraged to take sun protection measures to prevent progression to SCC.

1557 Background: The efficacy of cancer screening (cost effectiveness, reduced mortality) relies on a minimum threshold uptake rate. Target populations are asymptomatic with only average risk, and thus likely to avoid screening. We studied the characteristics of cancer-screening resistant individuals. Methods: The French nationwide observational survey, EDIFICE 6, was conducted online from 26 June-28 July 2017 on a core sample of 12 046 individuals (age 18-69 y). Representativeness was ensured by quota sampling on age, gender, profession, and stratification by geographical area and type of urban district. Multivariate stepwise logistic regression analyses were conducted with a common set of variables to identify factors likely to explain non-uptake of cancer screening. The analysis focused on individuals in the age range of target populations for organized programs: 50-69 y for breast (BC) and colorectal cancer (CRC) (N = 1954 and N = 4300, respectively) and 25-65 y for cervical cancer (CC) (N = 4499). Results: Of those who had never taken part in a screening program, 6% (N = 108) were in the target population for BC screening, 12% (N = 539) for CC, and 38% (N = 1625) for CRC screening. Items associated with not undergoing screening included: for BC, the statement "progress is accomplished through clinical research" rated as unimportant (OR = 2.14, 95% CI = [1.16-3.82]); social vulnerability (OR = 2.09, [1.36-3.25]); rating BC prevention programs as ineffective (OR = 1.60, [1.01-2.51]). For CC: living alone (OR = 2.31, [1.89-2.82]); manual worker (OR = 1.95, [1.21-3.05]); social vulnerability (OR = 1.83, [1.49-2.26]). For CRC: self-employed (OR = 1.83, [1.24-2.71]); rating CRC prevention programs as ineffective (OR = 1.76, [1.48-2.08]); current smoker (OR = 1.45, [1.25-1.68]); manual worker (OR = 1.40, [1.05-1.87]). Conclusions: Mistrust in clinical research—possibly linked to medical skepticism—and social vulnerability play major roles in resistance to BC screening. A disadvantaged socioeconomic profile has a negative impact on CC screening uptake and yet is an acknowledged risk factor for the disease. Self-employed people who mistrust cancer prevention are resistant to CRC screening. Our findings highlight the need for tailored education campaigns.